Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Nivolumab Yields Long-Term Survival Benefit in Advanced NSCLC

Key clinical point: A pooled analysis has confirmed the long-term survival benefit of using nivolumab versus docetaxel in patients with previously treated advanced non–small cell lung cancer.

Major finding: Across the four trials, the 4-year overall survival with nivolumab was 14%, including 11% for patients with under 1% programmed death–ligand 1 expression, and 19% for patients with a minimum of 1% programmed death–ligand 1 expression.

Study details: A combined analysis of four studies evaluating nivolumab in 664 patients with previously treated non–small cell lung cancer.

Disclosures: The study was funded by Bristol-Myers Squibb. The authors reported financial affiliations with AstraZeneca, Boehringer Ingelheim, Cellular Biomedicine Group, FLX Bio, Genentech, Novartis, Regeneron, and several others.

Citation:

Antonia SJ et al. Lancet Oncol. 2019 Aug 14. doi: 10.1016/S1470-2045(19)30407-3.